This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Abe, Ikubo & Katayama, Livtech Inc. — Teikyo University Biotechnology Research Center. Active years: 2011-2012.
Location History:
- Strasbourg, FR (2011)
- Kanagawa, JP (2012)
Company Filing History:
1 out of 1 
1 out of 1 Years Active: 2011-2012
Title: Rie Tajima: Innovator in Antibody Research
Introduction
Rie Tajima is a prominent inventor based in Kanagawa, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies with anti-tumor activity. Her work has the potential to impact cancer treatment and diagnostics.
Latest Patents
Rie Tajima holds two notable patents. The first patent is for an anti-human dlk-1 antibody that demonstrates anti-tumor activity in vivo. This invention includes the antibody specifically targeting hDlk-1, its fragments, hybridomas that produce the antibody, and various applications such as a tumor therapeutic agent and a diagnostic kit. The second patent also focuses on anti-hDlk-1 antibodies with similar properties and applications, emphasizing their role in tumor detection and treatment.
Career Highlights
Throughout her career, Rie Tajima has worked with several esteemed organizations. She has been associated with Livtech Inc., Teikyo University Biotechnology Research Center, and Abe, Ikubo & Katayama. Her work in these institutions has allowed her to advance her research and contribute to the scientific community.
Collaborations
Rie Tajima has collaborated with notable colleagues, including Koji Nakamura and Shankar Kumar. These partnerships have facilitated the exchange of ideas and expertise, further enhancing her research endeavors.
Conclusion
Rie Tajima's innovative work in antibody research showcases her dedication to advancing cancer treatment and diagnostics. Her patents reflect her commitment to developing effective therapeutic agents, making her a significant figure in the field of biotechnology.